

# Operationalization and implementation of pharmacological treatments for acutely suicidal patients: Insight from the trenches

Moderator: Suresh Durgam, MD

Panel:

Wieslaw Cubala, MD, PhD

Dong-Jing Fu, MD, PhD

Jonathan Javitt, MD, MPH

Emilie Olie, MD, PhD

**Suresh Durgam, MD**

Shares: Intra-Cellular Therapies, Inc

Paid position: Intra-Cellular Therapies, Inc

### **Wieslaw Jerzy Cubala, MD, PhD**

Grants: Alkermes, Auspex Pharmaceuticals, BMS, Celon, Cephalon, Ferrier, Forest Laboratories, GedeonRichter, GWPharmaceuticals, Janssen, KCR, Lilly, Lundbeck, Minerva, NIH, Orion, Otsuka, Sanofi, Servier

Honoraria: Adamed, Angelini, AstraZeneca, BMS, Celon, GSK, KRKA, Lekam, Lundbeck, Minerva, NeuroCog, Novartis, Orion, Pfizer, Polfa Tarchomin, Sanofi, Servier, Zentiva

Shares: PBKM

Advisory boards: Janssen, Sanofi

### **Dong Jing (DJ) Fu, MD, PhD**

Shares: Johnson & Johnson

Paid position: Director, Clinical Development, Janssen R&D, LLC

### **Jonathan Javitt, MD, MPH**

Shares: NeuroRx, Inc.

Paid position: CEO and Chairman, NeuroRx, Inc.

Other involvement: Adj. Professor, Johns Hopkins University School of Medicine

### **Emilie Olié, MD, PhD**

Grants: AstraZeneca, institut UPSA de la Douleur

Honoraria: AstraZeneca, BMS, Lundbeck, Janssen Cilag, Otsuka

Advisory boards: Janssen Cilag